Dark

Check out our Dark Pool Levels

CSLLY
CSL LTD SP/ADR
stock OTC ADR

EOD

Aug 4, 2026

22.96USD+5.418%(+1.18)88,081

Pre-market

0.00USD-100.000%(-21.64)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 18, 2022

01:09AM EST CSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PR Newswire

Dec 15, 2021

07:36AM EST CSL Behring Gets Accelerated CHMP Assessment For Etranacogene Dezaparvovec For Patients Living With Hemophilia B RTTNews

07:34AM EST EMA Grants Accelerated Assessment For CSL Behring's Haemophilia B Gene Therapy RTTNews

07:33AM EST CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec PR Newswire

07:31AM EST EMA Grants Accelerated Assessment for CSL Behring's Haemophilia B Gene Therapy PR Newswire

Dec 9, 2021

07:05AM EST ~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~ GlobeNewswire Inc

Dec 7, 2021

01:00PM EST Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults PR Newswire

Nov 23, 2021

08:36AM EST Seqirus : FDA Approves Multi-Dose Vial Presentation Of Adjuvanted, Cell-Based Pandemic Influenza Vaccine RTTNews

08:31AM EST Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of PR Newswire

Oct 26, 2021

07:06AM EDT CSL Plasma Opens 300th Plasma Donation Center in United States PR Newswire

Oct 19, 2021

07:31AM EDT Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021 PR Newswire

Oct 18, 2021

09:59PM EDT CSL Says Advances Novel Pipeline Spanning Six Therapeutic Areas, Four Scientific Platforms And Two Businesses RTTNews

08:30PM EDT Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines PR Newswire

Oct 15, 2021

10:59AM EDT Seqirus Receives FDA Approval Of Cell-Based Quadrivalent Influenza Vaccine RTTNews

10:57AM EDT Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, PR Newswire

Oct 14, 2021

08:01AM EDT Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents 2 to <18 Years of Age PR Newswire

Oct 4, 2021

08:05AM EDT Seqirus Receives Multi-year, $34.95 Mln U.S. Govt. Contract To Develop Two Pandemic Influenza Vaccines RTTNews

08:01AM EDT Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza PR Newswire

Sep 29, 2021

07:31AM EDT Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of PR Newswire

Sep 9, 2021

08:36AM EDT CSL's Global Chief Human Resources Officer Elizabeth Walker Appointed To Urban League Of Philadelphia's Board RTTNews

08:31AM EDT Urban League of Philadelphia Names CSL's Elizabeth Walker to Board of Directors PR Newswire

Aug 26, 2021

08:08AM EDT CSL Plasma To Provide Influenza Vaccination Vouchers To U.S. Plasma Donors RTTNews

08:07AM EDT CSL Plasma to Provide Flu Vaccines to U.S. Plasma Donors PR Newswire

Aug 19, 2021

08:32AM EDT Seqirus Plans To Accelerate Development Of Next Generation Of Messenger RNA Vaccine Technology RTTNews

08:31AM EDT Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, PR Newswire

Aug 9, 2021

09:20AM EDT Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance Treatment PR Newswire

Aug 3, 2021

09:13AM EDT CSL Behring : FDA Approves New BERINERT Administration Kit For Increased Patient Convenience RTTNews

09:10AM EDT FDA Approves New BERINERT(r) (C1 Esterase Inhibitor, Human (Intravenous)) PR Newswire

Jul 30, 2021

08:33AM EDT Seqirus Presents New Safety Data Demonstrating Safety Of Cell-Based Seasonal Influenza Vaccine On Pregnancy Outcomes RTTNews

08:31AM EDT Seqirus Presents New Safety Data Demonstrating Safety of Cell-Based Seasonal PR Newswire

Jun 14, 2021

04:06PM EDT Seqirus Co-Authors First Study to Assess Simultaneous Administration of PR Newswire

Jun 8, 2021

09:32AM EDT CSL Behring : Hizentra To Be Covered Under Same Medicare Benefit Category As Intravenous Immune Globulin RTTNews

09:01AM EDT Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients PR Newswire

May 16, 2021

01:15PM EDT Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days PR Newswire

May 14, 2021

07:31AM EDT Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation PR Newswire

May 6, 2021

07:06AM EDT CSL Behring Announces Closing of Global Commercialization and License Agreement PR Newswire

07:00AM EDT uniQure announces closing of commercialization and license GlobeNewswire Inc

May 3, 2021

09:06AM EDT Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age PR Newswire

Apr 29, 2021

08:31AM EDT Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients PR Newswire

Apr 20, 2021

08:37AM EDT Seqirus Publishes Evidence Supporting Effectiveness Of Adjuvanted Seasonal Influenza Vaccine In Adults 65 Yrs And Older RTTNews

08:31AM EDT Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious Diseases PR Newswire

Apr 19, 2021

05:00PM EDT Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to PR Newswire

Mar 25, 2021

08:31AM EDT Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season PR Newswire

Mar 18, 2021

08:34AM EDT Seqirus Announces Health Canada Approval Of Expanded Age Indication Of Cell-Based Quadrivalent Influenza Vaccine RTTNews

Mar 5, 2021

08:33AM EST Seqirus:FDA Oks Expanded Age Indication Of Cell-Based Quadrivalent Influenza Vaccine For People 2 Years Of Age & Older RTTNews

08:31AM EST Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older PR Newswire

Mar 3, 2021

05:20AM EST COVID-19 Convalescent Plasma Study Shows No Benefit, US NIH Stops Trial Benzinga

Jan 25, 2021

08:45AM EST Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community PR Newswire

Jan 7, 2021

09:03AM EST Lyfebulb Announces Call-to-Action for Submissions to the 2021 Innovation PR Newswire

Dec 7, 2020

08:31AM EST Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity PR Newswire

08:02AM EST Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of PR Newswire

Nov 19, 2020

07:01AM EST Angioedema (HAE) Value Efficacy and Specific Correction of C1-INH Deficiency When Choosing an HAE Therapy PR Newswire

Nov 16, 2020

08:31AM EST Urban League, CSL Behring Partner to Address Community Needs including Public PR Newswire

Nov 10, 2020

08:13AM EST CSL Behring To Present New Real-World Data On Outcomes Following Acute Coronary Syndrome RTTNews

08:10AM EST Syndrome at the American Heart Association (AHA) Virtual Scientific Sessions 2020 PR Newswire

Nov 8, 2020

07:53AM EST CSL Announced Commencement of Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne Benzinga

Nov 5, 2020

08:10AM EST CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce PR Newswire

Nov 2, 2020

08:06AM EST CSL Behring's Investigational Plasma-Derived Hemopexin Therapy For Sickle Cell Disease Granted Orphan Drug Designation RTTNews

08:02AM EST Orphan Drug Designation Granted for CSL Behring's Investigational PR Newswire

Oct 29, 2020

12:01PM EDT Vaccine (QIVc) Efficacy in Children 2 to <18 Years Old at the European Society for Paediatric Infectious Diseases (ESPID) PR Newswire

07:01AM EDT CSL Named as One of the World's Best Employers PR Newswire

Oct 21, 2020

09:01AM EDT Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020 PR Newswire

08:01AM EDT Shows Value of Adjuvanted Influenza Vaccine for Adults 65 Years and Older with Underlying Health Conditions PR Newswire

Oct 20, 2020

08:11AM EDT CSL Sees Producing COVID-19 Vaccine For Australia & Distribution To Global Markets Via COVAX Facility Toward End Of 2021 RTTNews

08:03AM EDT CSL's Broad Response to COVID-19 and Advancements across the Company's PR Newswire

Sep 28, 2020

08:12AM EDT CSL Behring : FDA Approves HAEGARDA For Prevention Of Hereditary Angioedema Attacks In Pediatric Patients RTTNews

08:10AM EDT Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients PR Newswire

Sep 21, 2020

08:33AM EDT Seqirus Publishes New RWE On Relative Effectiveness Of Adjuvanted Seasonal Influenza Vaccine In Adults RTTNews

08:31AM EDT Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Vaccines PR Newswire

Sep 16, 2020

08:31AM EDT Quadrivalent Influenza Vaccine in Preventing Influenza Related Hospitalizations in the U.S. 2017/18 Season PR Newswire

Jul 30, 2020

08:00AM EDT Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market PR Newswire

Share